1. Home
  2. RVPH vs XGN Comparison

RVPH vs XGN Comparison

Compare RVPH & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • XGN
  • Stock Information
  • Founded
  • RVPH 2006
  • XGN N/A
  • Country
  • RVPH United States
  • XGN United States
  • Employees
  • RVPH N/A
  • XGN N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • XGN Medical Specialities
  • Sector
  • RVPH Health Care
  • XGN Health Care
  • Exchange
  • RVPH Nasdaq
  • XGN Nasdaq
  • Market Cap
  • RVPH 36.4M
  • XGN 33.9M
  • IPO Year
  • RVPH N/A
  • XGN 2019
  • Fundamental
  • Price
  • RVPH $1.05
  • XGN $1.96
  • Analyst Decision
  • RVPH Strong Buy
  • XGN Buy
  • Analyst Count
  • RVPH 3
  • XGN 1
  • Target Price
  • RVPH $14.33
  • XGN $7.00
  • AVG Volume (30 Days)
  • RVPH 179.2K
  • XGN 20.4K
  • Earning Date
  • RVPH 08-12-2024
  • XGN 08-05-2024
  • Dividend Yield
  • RVPH N/A
  • XGN N/A
  • EPS Growth
  • RVPH N/A
  • XGN N/A
  • EPS
  • RVPH N/A
  • XGN N/A
  • Revenue
  • RVPH N/A
  • XGN $55,733,000.00
  • Revenue This Year
  • RVPH N/A
  • XGN $7.16
  • Revenue Next Year
  • RVPH N/A
  • XGN $16.16
  • P/E Ratio
  • RVPH N/A
  • XGN N/A
  • Revenue Growth
  • RVPH N/A
  • XGN 20.12
  • 52 Week Low
  • RVPH $1.04
  • XGN $1.30
  • 52 Week High
  • RVPH $6.80
  • XGN $2.95
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 31.82
  • XGN 53.16
  • Support Level
  • RVPH $1.17
  • XGN $1.93
  • Resistance Level
  • RVPH $1.25
  • XGN $2.21
  • Average True Range (ATR)
  • RVPH 0.11
  • XGN 0.10
  • MACD
  • RVPH 0.01
  • XGN 0.01
  • Stochastic Oscillator
  • RVPH 3.23
  • XGN 50.00

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: